Drug Research
Cellectricon introduces Cellaxess discovery platform
Cellectricon has launched a new Cellaxess elektra discovery platform for automated electric field manipulation of adherent cells. Developed in collaboration with pharma and biotechnology companies, the Cellaxess platform enables scalable field stimulation, compound delivery...
Drug Research
Aegis wins US patent for octreotide formulations
Aegis Therapeutics has received US patent covering pharmaceutical composition of octreotide. The octreotide formulations incorporate Aegis' Intravail/ProTek excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection. The Intravail/ProTek...
Drug Research
Cellectis introduces human iPS derived hepatocyte product
Cellectis stem cells, a business unit of Cellectis Group, has introduced hiPS-HEP, a human iPS derived hepatocyte product. The hiPS-HEP, with homogeneity, a long life span of stable CYP activity and reproducibility, provides a...
Drug Research
Antares, Watson Pharmaceuticals launch Gelnique 3% in US
Antares Pharma and Watson Pharmaceuticals have introduced Gelnique 3% (oxybutynin) gel 3%, for the treatment of overactive bladder. The product is available in a metered pump dispenser and is delivered transdermally, resulting in a...
Drug Research
Meridian, Teva settle epinephrine auto-injector pending patent litigation
Meridian Medical Technologies, a Pfizer subsidiary, and Teva have entered into a settlement agreement to resolve generic epinephrine auto-injector pending patent litigation. Under the terms of the agreement, Teva may launch a generic epinephrine...
Drug Research
Affymax, Takeda launch OMONTYS injection in US
Affymax and Takeda Pharmaceutical Company have announced the availability of OMONTYS injection to treat anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The once-monthly erythropoiesis-stimulating agent (ESA) for anemia is...
Drug Research
Watson introduces generic version of Fortamet
Watson Pharmaceuticals has introduced an authorized generic version of Fortamet as a part of an agreement with Shionogi. The company began the shipment of generic Fortamet (metformin hydrochloride extended-release tablets). Fortamet is indicated as an...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read